about
KASL clinical practice guidelines: management of hepatitis CSTAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liverEmerging concepts in immunity to hepatitis C virus infection.Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesIL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyIdentification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortRelation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver diseaseTrends in population-based studies of human genetics in infectious diseasesSequence analysis of the IL28A/IL28B inverted gene duplication that contains polymorphisms associated with treatment response in hepatitis C patientsGenome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis CPharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsA serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.Protective immunity against hepatitis C: many shades of gray.IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infectionReduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis CAssociation of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control studyHepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.Current and future therapies for hepatitis C virus infection.Persistent expression of hepatitis C virus non-structural proteins leads to increased autophagy and mitochondrial injury in human hepatoma cells.Clinical utility of pharmacogenomics in the management of hepatitis C.Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells.IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report.Predictive factors associated with hepatitis C antiviral therapy response.Cytokines and STATs in Liver Fibrosis.Recent trends in the treatment of chronic hepatitis CRs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus.PharmGKB summary: peginterferon-α pathway.Pharmacogenomics of hepatitis C infections: personalizing therapy.Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection.Impact of host responses on control of hepatitis C virus infection in Chinese blood donors.Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus (HIV) patients in a large HIV clinic in South Korea.Impact of host and virus genome variability on HCV replication and response to interferon.Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus.Chronic hepatitis C genotype 1 virus: who should wait for treatment?Individualization of chronic hepatitis C treatment according to the host characteristics.Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.
P2860
Q26752471-66950960-3D5F-4949-A48C-29A59A638382Q27000742-C6AA2F03-8C10-4B59-AB7D-8B1B69CA5158Q27002588-28300E6B-7451-4A83-B3A9-EB13779132F9Q28272678-01F42BF6-BC92-43DA-BF10-0A91929824B6Q28477057-32A6AA55-4577-4574-BE22-E727CBE77BBFQ28478435-64B6F626-D5D9-4C92-9145-36E0D1C7ACF5Q28483964-2133B466-030C-4D49-9350-71D62C9E6436Q28732216-1283691C-23D2-4390-9E40-ED69463584D1Q28732905-74B82AAA-F51D-409E-90D1-261C47D8E774Q28943467-02577E37-EFC0-472C-9051-0F989C8DA5C5Q30365599-29C6C9BF-D0DD-49E5-B4A6-B272EC0AE9CBQ30459124-B9A3D339-B5D5-4548-B95C-326AB81F1E33Q33759224-F402AA4A-A84A-4B8E-8653-71651ACB9BCFQ33867243-059CFABB-B680-4B56-83AF-31F5D6638E7BQ33887760-29894B1A-D0B6-4AC9-A224-A7FBC51A23A7Q33903850-94D4C266-BF08-4419-9112-10B2EEDA199DQ34008754-1B64AE3F-D4CE-4F81-B7CE-81522DC9144AQ34036762-7328FEC1-D8CC-48FF-97D0-1703EEA504E7Q34099283-6B9235C0-234E-4889-90F4-3D2B95D61274Q34464613-10E53124-75F0-4A48-9E93-DEC7428F422BQ34484305-AB977DBF-B07E-4846-A431-C68ACED91524Q34485088-40840423-EECF-4B93-910D-4B6924944D3CQ34539324-62963381-6BEC-4507-A605-E623B8A6255FQ35110983-A64E1F19-8694-45C4-A96D-9269B1950CA1Q35540229-81049B7A-1C34-439A-AD55-4FDD40CB519FQ35790397-7CC9BBA6-C601-4957-A50B-9930CE2FA357Q35867085-80995824-3214-4239-9938-8396F66F03B9Q35890619-14AEADEC-8E01-44BA-94F4-9D55CCD58A3AQ36478562-D846584D-8F5F-4F15-9326-D0F2A55F846DQ36590755-15D1DDBB-54FE-4C81-A8B5-25CCECF54CADQ36632938-9F60D5E0-458B-4044-ABE0-58DF86232503Q37009894-4BE38409-76EA-40D5-AD82-25022EE502A1Q37078196-6EBD0AF3-DEAB-41AE-AE2B-233AD042782EQ37081478-40B816E9-41F3-497C-9978-1CF9EDDBEA3AQ37230981-5974DA32-E3AB-4337-A2A7-6FC1CBB1148CQ37540221-B7E053C5-6DA1-4A02-84C6-D4909A5ACD33Q37654449-203F2EFD-4547-4DF2-899D-2CB06E3A5FA1Q37654502-73249DD7-88D3-41DE-AFA3-5B309F08149CQ37879701-45D61226-7E07-4C3D-BDC5-3D42B880E661Q37921307-1EF064BB-CFA2-47D4-95F7-A05C8A51F317
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis C pharmacogenetics: state of the art in 2010.
@en
Hepatitis C pharmacogenetics: state of the art in 2010.
@nl
type
label
Hepatitis C pharmacogenetics: state of the art in 2010.
@en
Hepatitis C pharmacogenetics: state of the art in 2010.
@nl
prefLabel
Hepatitis C pharmacogenetics: state of the art in 2010.
@en
Hepatitis C pharmacogenetics: state of the art in 2010.
@nl
P2093
P2860
P50
P356
P1433
P1476
Hepatitis C pharmacogenetics: state of the art in 2010.
@en
P2093
Alessandra Mangia
David B Goldstein
David L Thomas
David R Booth
Jeffrey S Murray
John G McHutchison
Kevin V Shianna
Pharmacogenetics and Hepatitis C Meeting Participants
Yasuhito Tanaka
P2860
P304
P356
10.1002/HEP.24052
P407
P577
2011-01-01T00:00:00Z